Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
FUJIFILM Corporation announced that it has completed the acquisition of Biogen Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen.
Great Bay Bio, a leading biotechnology company dedicated to innovative biologics CMC (Chemistry Manufacturing and Controls) and development of biologics development big data platform, the board is pleased to announce the introduction of a new non-executive director, Mr. William Kung.
Neos Therapeutics, Inc. announced that it will report its second quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, August 8, 2019.
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
MyoKardia, Inc., announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019.
Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.
Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.